Evidence mapPaperPMID 34239693Full record

ArticleOxidative medicine and cellular longevity2021

Analysis of Molecular Mechanism of Erxian Decoction in Treating Osteoporosis Based on Formula Optimization Model.

Lang Yang, Liuyi Fan, Kexin Wang, Yupeng Chen, Lan Liang, Xuemei Qin, Aiping Lu, Peng Cao, Bin Yu, Daogang Guan and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Aging · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Lang YangDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-2759-6014
Liuyi FanDepartment of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Kexin WangModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, China.
Yupeng ChenDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Lan LiangDepartment of Computer Science, Hong Kong Baptist University, Hong Kong SAR, China.
Xuemei QinModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, China.
Aiping LuInstitute of Integrated Bioinformedicine and Translational Science, Hong Kong Baptist University, Hong Kong, China.
Peng CaoDepartment of Surgery, Chinese People's Liberation Army 96608 Military Hospital, China.
Bin YuDepartment of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-7549-9753
Daogang GuanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0003-1414-0189
Junxiang PengDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-4380-7301
Nanfang Hospital · CNHong Kong Baptist University · HKSouthern Medical University · CNChinese People's Liberation Army · CNShanxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis (OP) is a highly prevalent orthopedic condition in postmenopausal women and the elderly. Currently, OP treatments mainly include bisphosphonates, receptor activator of nuclear factor kappa-B ligand (RANKL) antibody therapy, selective estrogen receptor modulators, teriparatide (PTH1-34), and menopausal hormone therapy. However, increasing evidence has indicated these treatments may exert serious side effects. In recent years, Traditional Chinese Medicine (TCM) has become popular for treating orthopedic disorders. Erxian Decoction (EXD) is widely used for the clinical treatment of OP, but its underlying molecular mechanisms are unclear thanks to its multiple components and multiple target features. In this research, we designed a network pharmacology method, which used a novel node importance calculation model to identify critical response networks (CRNs) and effective proteins. Based on these proteins, a target coverage contribution (TCC) model was designed to infer a core active component group (CACG). This approach decoded the mechanisms underpinning EXD's role in OP therapy. Our data indicated that the drug response network mediated by the CACG effectively retained information of the component-target (C-T) network of pathogenic genes. Functional pathway enrichment analysis showed that EXD exerted therapeutic effects toward OP by targeting PI3K-Akt signaling (hsa04151), calcium signaling (hsa04020), apoptosis (hsa04210), estrogen signaling (hsa04915), and osteoclast differentiation (hsa04380) via JNK, AKT, and ERK. Our method furnishes a feasible methodological strategy for formula optimization and mechanism analysis and also supplies a reference scheme for the secondary development of the TCM formula.

Indexed as

Drugs, Chinese HerbalFemaleHumansMaleOsteoporosisDrugs, Chinese Herbaler-xian decoction

Identifiers

PMID34239693
PMCPMC8238601
OpenAlexW3174547150

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.